A single-center, self-controlled, single-arm pilot clinical trial to assess the effect of lamivudine (3TC) on neurocognitive impairment biomarkers and type-I IFN (interferon)-stimulated genes in the plasma of patients with Mild Cognitive Impairment (MCI)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514330-20-00

Acronym

LAMIFERON

Enrollment

Registered

2024-07-31

Start date

2024-10-25

Completion date

Unknown

Last updated

2024-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive impairment due to Alzheimer Disease

Brief summary

Percentage of change of pTau-217, total Tau, NfL, GFAP, Aβ42, Aβ40, and ratio in plasma from baseline visit to week 24 visit. Safety and tolerability as measured by incidence, nature, and severity of treatment adverse events (AE), serious AE (SAE), and AE leading to withdrawal.

Detailed description

Fold change of type-I IFN-stimulated genes in plasma and cryopreserved PBMCs from baseline visit to week 24 visit.

Interventions

DRUGLamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Fold change of type-I IFN-stimulated genes in plasma and cryopreserved PBMCs from baseline visit to week 24 visit.	—

Primary

Measure	Time frame
Percentage of change of pTau-217, total Tau, NfL, GFAP, Aβ42, Aβ40, and ratio in plasma from baseline visit to week 24 visit. Safety and tolerability as measured by incidence, nature, and severity of treatment adverse events (AE), serious AE (SAE), and AE leading to withdrawal.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026